Brokerages Expect ADMA Biologics Inc (ADMA) to Announce ($0.51) EPS
Shares of ADMA Biologics Inc (NASDAQ:ADMA) have been given a consensus broker rating score of 1.33 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and two have given a strong buy rating to the company. ADMA Biologics’ rating score has improved by 20.4% in the last three months as a result of a number of analysts’ ratings changes.
Analysts have set a 1-year consensus price objective of $7.63 for the company and are expecting that the company will post ($0.51) earnings per share for the current quarter, according to Zacks. Zacks has also given ADMA Biologics an industry rank of 161 out of 265 based on the ratings given to its competitors.
ADMA has been the subject of a number of analyst reports. Maxim Group reissued a “buy” rating and issued a $8.00 price objective (down from $13.00) on shares of ADMA Biologics in a research note on Monday, December 11th. Raymond James Financial upgraded shares of ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 target price for the company in a research report on Tuesday, November 14th.
An institutional investor recently raised its position in ADMA Biologics stock. Iguana Healthcare Management LLC increased its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 276.7% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 565,000 shares of the biotechnology company’s stock after acquiring an additional 415,000 shares during the quarter. Iguana Healthcare Management LLC owned about 2.19% of ADMA Biologics worth $1,740,000 at the end of the most recent quarter. Institutional investors own 32.78% of the company’s stock.
Shares of ADMA Biologics (ADMA) traded down $0.12 during midday trading on Friday, hitting $3.57. 199,337 shares of the stock were exchanged, compared to its average volume of 142,019. The company has a current ratio of 2.36, a quick ratio of 1.35 and a debt-to-equity ratio of 2.26. The stock has a market capitalization of $95.18, a PE ratio of -4.35 and a beta of 2.50. ADMA Biologics has a 1 year low of $2.01 and a 1 year high of $5.74.
ADMA Biologics Company Profile
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.